SCHEMBL17697692

SCHEMBL17697692

O=S(=O)(Cl)c1cnc2ccc(Cl)cn12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.46
TNF P01375 1/20 0.41
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37
EIF2AK4 Q9P2K8 9/20 0.37
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
FLT3 P36888 2/20 0.35
IRAK4 Q9NWZ3 2/20 0.35
NRAS P01111 1/20 0.35
PRMT5 O14744 1/20 0.35
WDR77 Q9BQA1 1/20 0.35
TGFBR1 P36897 1/20 0.34
LCK P06239 1/20 0.34
RET P07949 1/20 0.34
PDGFRB P09619 1/20 0.34
CDK7 P50613 1/20 0.34
BLK P51451 1/20 0.34
IRAK1 P51617 1/20 0.34
CCNH P51946 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17697688 0.81 MAP3K14 (0.41) TNFEIF2AK4FLT3TGFBR1CDK7
SCHEMBL17697727 0.78 RIPK2 (0.38) TNFIRAK4PRMT5WDR77TGFBR1
SCHEMBL17697709 0.76 CYP1A2 (0.44) POLBNPC1RAB9AMEN1KMT2A
SCHEMBL30977360 0.75 KDR (0.40) TNFNPC1RAB9AFLT3PRMT5
SCHEMBL792707 0.74 ADORA3 (0.44) NPC1RAB9AFLT3
SCHEMBL28041698 0.74 POLB (0.54) POLBNPC1RAB9AEIF2AK4MEN1
SCHEMBL17697685 0.73 MET (0.60) FLT3NRAS
SCHEMBL3325146 0.71 POLB (0.51) POLBNPC1RAB9AEIF2AK4MEN1
SCHEMBL16404632 0.71 POLB (0.56) POLBNPC1RAB9AEIF2AK4MEN1
SCHEMBL3020269 0.71 POLB (0.51) POLBNPC1RAB9AEIF2AK4MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3012259-B1 FIVE-MEMBERED HETEROCYCLIC PYRIDINE COMPOUNDS AND PREPARATION METHOD AND USE THEREOF SHANGHAI INST MATERIA MEDICA CAS (CN) 2020-06-03 EP disclosed
US-9988381-B2 Five-member-heterocycle fused pyridine compounds, method of producing the same, and use thereof SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) 2018-06-05 US disclosed
US-20160137640-A1 FIVE-MEMBER-HETEROCYCLE FUSED PYRIDINE COMPOUNDS, METHOD OF PRODUCING THE SAME, AND USE THEREOF SHANGHAI HAIHE PHARMACEUTICAL CO. LTD. (CN) 2016-05-19 US disclosed
EP-3012259-A1 FIVE-MEMBERED HETEROCYCLIC PYRIDINE COMPOUNDS AND PREPARATION METHOD AND USE THEREOF Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) 2016-04-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160137640-A1 FIVE-MEMBER-HETEROCYCLE FUSED PYRIDINE COMPOUNDS, METHOD OF PRODUCING THE SAME, AND USE THEREOF ABL1, JAK2, LCK POLB 4761/4885TNF 1549/4885NPC1 3450/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.